{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:37:10Z","timestamp":1792679830681,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1209,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.ccr.2010.03.011","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T01:32:46Z","timestamp":1274146366000},"page":"427-442","source":"Crossref","is-referenced-by-count":226,"title":["Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate"],"prefix":"10.1016","volume":"17","author":[{"given":"Bin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinwei","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keh-Dong","family":"Shiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia S.","family":"Huettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Shultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Holyoake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccr.2010.03.011_bib1","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib2","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V85.12.3636.bloodjournal85123636","article-title":"Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages","volume":"85","author":"Bhatia","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccr.2010.03.011_bib4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ccr.2010.03.011_bib5","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Bruserud","year":"2007","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ccr.2010.03.011_bib6","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1038\/sj.onc.1207893","article-title":"Histone deacetylase inhibitors specifically kill nonproliferating tumour cells","volume":"23","author":"Burgess","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2010.03.011_bib7","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: An exit from cell cycle control","volume":"9","author":"Chen","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccr.2010.03.011_bib9","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib11","doi-asserted-by":"crossref","first-page":"9339","DOI":"10.1158\/0008-5472.CAN-06-3126","article-title":"Cancer stem cells\u2014perspectives on current status and future directions: AACR Workshop on cancer stem cells","volume":"66","author":"Clarke","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2010.03.011_bib12","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib13","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib14","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib16","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-06-0980","article-title":"Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells","volume":"12","author":"Fiskus","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccr.2010.03.011_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: Clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ccr.2010.03.011_bib19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.onc.1209080","article-title":"Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology","volume":"25","author":"Gordon","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ccr.2010.03.011_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2010.03.011_bib22","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib23","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib24","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1182\/blood-2003-03-0768","article-title":"Inducible expression of BCR\/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome","volume":"102","author":"Huettner","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib26","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib28","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/sj.leu.2403785","article-title":"Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in\u00a0vitro","volume":"19","author":"Jorgensen","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2010.03.011_bib29","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib30","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.leu.2405086","article-title":"Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors","volume":"22","author":"Konig","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ccr.2010.03.011_bib31","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib32","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/nm1296-1329","article-title":"Identification of primitive human hematopoietic cells capable of repopulating NOD\/SCID mouse bone marrow: Implications for gene therapy","volume":"2","author":"Larochelle","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib33","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.stem.2008.09.005","article-title":"Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity","volume":"3","author":"Laurenti","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ccr.2010.03.011_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-230X(04)91004-4","article-title":"Histone deacetylase inhibitors","volume":"91","author":"Marks","year":"2004","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ccr.2010.03.011_bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1042\/bss0710157","article-title":"Antioxidant and cytoprotective responses to redox stress","volume":"71","author":"Mathers","year":"2004","journal-title":"Biochem. Soc. Symp."},{"key":"10.1016\/j.ccr.2010.03.011_bib36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.devcel.2005.08.015","article-title":"Drosophila E2F1 has context-specific pro- and antiapoptotic properties during development","volume":"9","author":"Moon","year":"2005","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ccr.2010.03.011_bib37","first-page":"5126","article-title":"Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccr.2010.03.011_bib38","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2002-08-2675","article-title":"Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells","volume":"101","author":"Nimmanapalli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib39","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ccr.2010.03.011_bib41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ccr.2010.03.011_bib42","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ccr.2010.03.011_bib43","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccr.2010.03.011_bib44","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood.V91.7.2406","article-title":"High level engraftment of NOD\/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase","volume":"91","author":"Wang","year":"1998","journal-title":"Blood"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610810001029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610810001029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T16:01:07Z","timestamp":1591286467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610810001029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1535610810001029"],"URL":"https:\/\/doi.org\/10.1016\/j.ccr.2010.03.011","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4106956.3885054","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}